Adam graduated as a pharmacist and a physician from Leiden University and was trained as a clinical pharmacologist in London. He was involved in early drug development from 1981 to today and started his career with the first administration to humans of lamotrigine. This antiepileptic is now part of the standard therapy for epilepsy and bipolar disorders. He was subsequently European project leader for one of the first biotechnologically produced medicines, rtPA for Wellcome Biotech. He then founded CHDR in Leiden that grew from a three-person startup to an internationally renowned early phase CRO uniquely at the crossroads of academia and industry. He was chairman of the Netherlands Competent Authority for Clinical Trials and National Ethics Committee (CCMO). He was Editor in Chief of the British Journal of Clinical Pharmacology and is now Editor for a series on EMA guidelines. He always remained attached to clinical work, at the Department of Nephrology of Leiden University Medical Center and lately as a general physician for Ukrainian refugees. Adam is an active amateur clarinettist and is married to a physician.
Broadening our aim
The addition of Prof. Cohen broadens AVIGI's ambitions to aim wider and scope non-oncology indications to our target's potential. With strong foundational disciplines guiding our leadership we're set up for success. Our scientific advisory team now includes:
- Prof. Hermen Overkleeft - Scientific Advisor
- Prof. Gideon Davies – Scientific Advisor
- Prof. Dr. Adam Cohen – Clinical Advisor
- Dr. Alessandro Noseda – Medical Advisor
- Dr. Liang Wu – Advisor structural biology
“We're standing on the shoulders of giants” noted Arian, AVIGI’s Development Associate. “Working with exeptional humans is both rewarding and humbling.” 
About AVIGI Therapeutics
AVIGI is a spinout from Leiden University dedicated to transforming the treatment landscape for advanced solid tumors and diabetic complications. Founded by scientists and developers who are rethinking conventional drug design, AVIGI combines deep scientific insight and advanced chemistry to create innovative treatment technologies.